It is well acknowledged that inflammation and immune system contribute to cancer pathogenesis ([@bib12]). In colorectal cancer (CRC), one of the leading causes of cancer deaths worldwide ([@bib14]), heavier inflammatory infiltrate in tumour area has been associated with better prognosis in an assemblage of studies ([@bib31]), emphasising the significance of an effective immune response in controlling tumour progression ([@bib35]).

However, the lack of a standardised analysis method has been a major concern ([@bib10]; [@bib31]), and so far, none of the proposed immunohistochemical cell markers ([@bib22]; [@bib26]; [@bib9]; [@bib41]) or inflammatory classifications based on inspecting haematoxylin and eosin (H&E) slides ([@bib13]; [@bib17]; [@bib25]) have been incorporated into routine clinical practice. There are only limited amount of data on the interrelationships between different inflammatory cell types ([@bib20]) and inflammatory cell reaction grading methods ([@bib33]; [@bib29]) in CRC, which would be essential in evaluating their relative significance.

Klintrup--Mäkinen (K--M) score for peritumoural inflammation utilising H&E slides has been acknowledged as one of the most promising overall inflammatory reaction grading systems in CRC ([@bib31]). It has been shown to be reproducible and to harbour stage-independent prognostic value in several studies ([@bib17]; [@bib32], [@bib33]; [@bib29]), exceeding the value of Jass classification ([@bib33]) and individual inflammatory cell counts from H&E slides ([@bib29]). Although being linked with heavy peritumoural macrophage and lymphocyte infiltration based on evaluations utilising H&E slides ([@bib17]; [@bib29]), the distinct cell types contributing to high K--M score still remain equivocal.

In this study we systematically quantitated the densities of eight inflammatory cell types from intra- and peritumoural regions. We analysed a prospectively recruited group of 117 CRC patients utilising an accurate image analysis-based method ([@bib41]). The main aims of the study were to enlighten the mutual relationship between different inflammatory cell types in CRC and to clarify the contributions of individual cell types to K--M-classification of peritumoural inflammation. As a deficient mismatch repair (MMR) system is known to contribute to the CRC-associated inflammatory reaction ([@bib37]), we also characterised the immune cell infiltration in relation to MMR screening status.

Materials and methods
=====================

Patients
--------

The study was based on an earlier described prospectively recruited group of 149 CRC patients, who had signed an informed consent for the study and were operated in Oulu University Hospital in 2006--2010 ([@bib16]). The data collection procedures and analysis methods were designed before the start of the collection of study material. The clinical details of the patients were collected from the case records, including the data on recurrences by the 24-month follow-up visit. Of the 149 patients, 32 (21.5%) patients who received preoperative radiotherapy or chemoradiotherapy (RT/CRT) were excluded as RT/CRT is a potential confounding factor, affecting especially the inflammatory parameters of the tumours ([@bib21]). Thus, the final study included 117 (78.5%) of 149 CRC patients ([Table 1](#tbl1){ref-type="table"}). The study design was approved by the Ethical Committee of Oulu University Hospital (58/2005, 184/2009).

Histopathological analysis
--------------------------

The samples from surgical specimens were fixed in 10% buffered formalin solution and embedded in paraffin, and 5 *μ*m sections were stained with H&E. Staging was done according to TNM6 ([@bib38]) and grading according to the WHO criteria ([@bib11]). The TNM6 was chosen to allow better comparability with previous studies. We evaluated peritumoural inflammatory reaction from H&E slides according to the K--M criteria, where 0 denoted no increase of inflammatory cells, 1 denoted mild and patchy increase of inflammatory cells, 2 denoted a band-like infiltrate at the invasive margin with some evidence of destruction of cancer cell islets, and 3 denoted a very prominent inflammatory reaction with frequent destruction of cancer cell. These scores were then classified into low grade (0--1) and high grade (2--3) ([@bib17]).

TMA construction
----------------

We constructed a tissue microarray (TMA) for the analysis of inflammatory cell densities. We used the H&E slides to select optimal sample locations. Depending on the size of the tumour, we manually sampled 1--4 (median 3) cores of 3.0 mm diameter for each case yielding an overall tumour area of 7.1--28.3 mm^2^. Of these cores, 1--3 (median 2) were taken from the invasive front of the tumour containing the point of deepest invasion and the rest from intratumoural locations with an aim to avoid necrotic areas.

Immunohistochemistry
--------------------

Sections (3.5 *μ*m) cut from paraffin-embedded specimens were deparaffinised in xylene and rehydrated through graded alcohol series. For antigen retrieval, the sections were pretreated with TRIS-EDTA, pH 9.0, in a microwave oven at 800 W for 2 min and at 150 W for 15 min. After neutralising endogenous peroxidase activity, the sections were incubated at room temperature with diluted primary antibodies ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Bound antibodies were detected using EnVision system (Dako, Copenhagen, Denmark). The 3,3\'-Diaminobenzidine (DAB) was used as the chromogen and haematoxylin as the counterstain. The MMR enzyme immunohistochemistry was conducted as described previously ([@bib40]).

We counted the inflammatory cells using an earlier described computer-based method ([@bib41]). We photographed the sections from different locations (peritumoural, intratumoural stromal and intratumoural epithelial) with Olympus DP25 camera (Olympus, Center Valley, PA, USA) attached to Nikon Eclipse E600 microscope (Nikon, Tokyo, Japan) utilising × 20 and × 10 objectives. We used ImageJ-based ([@bib1]) set of programmes in counting the positive cells based on their size, shape, and the intensity of positivity ([@bib41]). We counted intraepithelial immune cells (CD3 and CD8) manually from the captured images because of the inadequacy of the automatic cell counting to segregate the intraepithelial cells from those in the stroma. All the cell counts were expressed as cells mm^−2^. The MMR screening status was evaluated by MLH1 and MSH2 immunohistochemistry as described earlier ([@bib40]).

Statistical analyses
--------------------

Normally distributed continuous variables are presented as mean (s.d.), whereas other continuous variables are presented as median (IQR). The statistical analyses were conducted using IBM SPSS Statistics 19 (IBM, Chicago, IL, USA). Pearson\'s correlation coefficients (*r*) were used in determining the correlations between different immune cell types. A logarithmic transformation was applied to variables with positive skewness. Nearest neighbour method with standardised squared Euclidean distance was applied in hierarchical clustering of different inflammatory cell variables. The statistical significances of the associations between immune cells and K--M score, MMR screening status, and stage were analysed by Mann--Whitney *U-*test or Kruskal--Wallis test. Cross-tabulation and *χ*^2^ test or Fisher\'s exact test were used in determining the associations between K--M score, MMR screening status, and stage. Receiver operating characteristics (ROC) analysis for optimal cutoff points, Kaplan--Meier method, and log-rank test for statistical significance were used in the recurrence analysis. The *P-*value of \<0.05 was considered statistically significant.

Results
=======

Characteristics of immune cell infiltration
-------------------------------------------

Of the 117 cases, 65 (55.6%) showed high-grade K--M score, signifying a band-like inflammatory infiltrate at the invasive margin with evidence of cancer cell destruction. Immunohistochemistry was used to further characterise the inflammatory infiltrate and it was successful in all 117 cases ([Figure 1](#fig1){ref-type="fig"}). The CD3^+^ T cells were the most frequent in all the tumour locations, followed by CD68^+^ cells (mainly monocyte--macrophage lineage), CD8^+^ T cells, and FoxP3^+^ T cells. At the invasive front, the median CD8^+^ and FoxP3^+^ T-cell counts were 30.4% and 26.7% of the amount of CD3^+^ T cells, respectively, and in the intratumoural stroma, 19.3% and 29.8%, respectively. Peritumoural inflammatory infiltrate was, in general, heavier than intratumoural stromal infiltrate.

Interrelationships between inflammatory cells and their contributions to K--M classification
--------------------------------------------------------------------------------------------

We analysed the interrelationships between different inflammatory cells by calculating Pearson\'s correlation coefficients ([Table 2](#tbl2){ref-type="table"}) and by hierarchical clustering of the inflammatory cell markers ([Figure 2](#fig2){ref-type="fig"}). Different inflammatory cells had high positive correlations with each other, except for mast cells and CD1a^+^ immature dendritic cells (DCs), which also clustered furthest from T cells in hierarchical clustering. The CD83^+^ mature DCs clustered with T cells ([Figure 2](#fig2){ref-type="fig"}), highlighting their importance for the adaptive immune response against the tumour. Peritumoural and intratumoural cell counts of each cell type showed substantial concordance, with Pearson\'s *r* varying from 0.434 (CD83) to 0.714 (CD3).

The contributions of the individual inflammatory cells to K--M score are presented in [Table 3](#tbl3){ref-type="table"}. High K--M score associated with higher densities of CD3^+^, CD8^+^, and FoxP3^+^ T cells, CD68^+^ cells, CD83^+^ mature DCs, and neutrophils. Although based on the evaluation of the inflammatory reaction at the invasive front, the classification notably showed excellent correlation with the densities of intratumoural -- in addition to peritumoural -- inflammatory cells.

Immune cell infiltration in relation to stage and MMR screening status
----------------------------------------------------------------------

Higher TNM stage -- in particular, stage IV denoting the presence of distant metastases -- associated with generally lower immune cell densities ([Table 4](#tbl4){ref-type="table"}), especially, with lower densities of FoxP3^+^, CD3^+^, and CD8^+^ T cells, as well as CD83^+^ DCs, all of which had been shown to be related to higher K--M score ([Table 3](#tbl3){ref-type="table"}). Thus, unsurprisingly, K--M score also inversely correlated with stage (*P*=1.2E−3; [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Conversely, mast cells, stromal CD68^+^ cells, stromal CD1a^+^ cells, and stromal neutrophils did not have significant associations with stage. With the exception of mast cells, peritumoural immune cell densities had higher associations with stage than intratumoural densities of the same cell types.

The MMR-deficient cases had a trend towards higher K--M score (*P*=0.062; [Supplementary Table 3](#sup1){ref-type="supplementary-material"}), and in the detailed analysis, MMR deficiency associated with increased amounts of intra- and peritumoural CD3^+^ and CD8^+^ T cells ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}).

Recurrence analysis
-------------------

Finally, we carried out a 24-month recurrence analysis for 80 (68.4%) of 117 patients, of whom 15 (18.8%) had a recurrence. Of the 117 patients, 22 (18.8%) were excluded because they underwent a palliative operation and 15 (12.8%) were excluded because they did not have 24-month follow-up data available. The ROC analysis was used to compare the discriminatory capacity of different variables as well as in setting optimal cutoff points ([Table 5](#tbl5){ref-type="table"}). Four-tiered K--M classification, FoxP3, and CD3 yielded the highest areas under the curves (AUCs). Log rank test indicated significant associations with recurrences for four-tiered K--M score, peritumoural T cells (CD3^+^), and stromal and peritumoural FoxP3^+^ T cells ([Table 5](#tbl5){ref-type="table"}). Also, several other cell types showed tendencies for lower recurrence rates in higher cell densities (AUC \>0.500) but lacked statistical significance in the short follow-up. Currently, the short follow-up did not enable a construction of sensible multivariate survival models.

Discussion
==========

This study aimed to enlighten the interrelationships between different inflammatory cell types and K--M overall classification for peritumoural inflammation in CRC. To our knowledge, this is so far the most extensive study on this subject, including markers of both adaptive (CD3, CD8, and FoxP3) and innate immunity (CD68, neutrophil elastase, and mast cell tryptase), as well as antigen prsenting cells (APCs) (CD1a, CD68, and CD83) serving as a link between the two ([@bib2]). We found that most constituents of CRC inflammatory infiltrate show notable positive correlations between each other and the K--M score. This finding, along with the capability of K--M score in predicting recurrences, supports the value of overall inflammatory assessments.

The accurate, computer-based cell counting method ([@bib41]) allowed us to look into the role of individual cell types in CRC-associated immune responses. We utilised a TMA that was specifically built for immune cell evaluations from different tumour locations. The substantial tumour area of 7.1--28.3 mm^2^ -- for comparison, for example, 12.5--50.0 times larger than in the noteworthy study by [@bib24] assessing the prognostic effect of intraepithelial T cells -- decreased the risk of sampling error, whereas the avoidance to sample necrotic areas reduced the potential impact of necrosis as a confounding factor ([@bib30]). Compared with whole-tissue samples, the TMA enabled the standardisation of analysed locations that was beneficial in the study of interrelationships between immune cells.

T lymphocytes, the hallmark of cell-mediated adaptive immunity, are considered essential in tumour immunosurveillance ([@bib35]), as shown in dozens of reports of their prognostic significance in CRC ([@bib31]), as well as in other solid tumours ([@bib8]). Our study included CD3 as pan-T-cell marker, CD8 representing cytotoxic T cells, and FoxP3 as a marker for regulatory T (T~Reg~) cells, all of which have been associated with better survival and stage-independent prognostic value in CRC ([@bib22]; [@bib9]; [@bib34]; [@bib7]). Still, some discrepancy exists for the significance of T~Reg~ cells. High T~Reg~ cell infiltration has been linked with poor survival in, for example, ovarian ([@bib4]) and breast cancer ([@bib3]), which is in accordance with the role of T~Reg~ cells in dampening immune response ([@bib43]). Moreover, some studies have failed to show an association between FoxP3^+^ T-cell infiltration and survival in CRC ([@bib36]). However, our results support the majority of the published results linking T~Reg~ cells with favourable outcome in CRC ([@bib34]; [@bib7]), as high FoxP3^+^ T-cell count had the highest association with lower recurrences of all the individual cell markers and FoxP3^+^ T cells clustered along with other T cells in hierarchical clustering analysis. Nevertheless, the mechanisms accounting for the impact of T~Reg~ cells in CRC and for the inconsistencies in their roles in different cancers remain unclear.

Dendritic cells are important APCs responsible for the induction of adaptive immune responses ([@bib2]). After capturing antigens, immature DCs mostly reside to lymph nodes to facilitate maturation and antigen presentation to T cells. The significance of local mature DCs in CRC immunity was originally described by [@bib39], who found that mature DCs make small aggregates with T cells in the invasive margin of CRC to promote T-cell activation. In agreement with these findings, we found high numbers of mature DCs both intra- and peritumourally. This suggests that after antigen capture, some of the DCs reside to tumour stroma and mature, potentially contributing to T-cell activation in tumour stroma. This phenomenon is not unique to CRC but can also be observed in other malignancies, for example, in non-small-cell lung cancer ([@bib5]). In our study, CD1a^+^ immature DCs did not associate with stage and clustered far apart from other cells in hierarchical clustering, whereas CD83^+^ mature DCs had a strong association with lower stage and clustered along with CD3^+^ T cells. This result supports the importance of tumour-associated mature DCs in effective T-cell responses against the tumour and encourages further studies addressing different DC subgroups in CRC.

Tumour-associated macrophages (TAMs) may contribute to antigen presentation and cancer cell phagocytosis ([@bib19]), and accordingly, high TAM infiltration at the invasive front of CRC has been associated with improved survival ([@bib17]; [@bib6]). However, TAMs polarised towards M2 phenotype may promote tumour growth by, for example, inducing cancer cell proliferation (by the secretion of growth factors), angiogenesis (by the secretion of vascular growth factors), and metastasis (by the secretion of matrix metalloproteinases) ([@bib19]). Indeed, conversely to peritumoural TAMs, intratumoural TAMs have been linked with CRC progression ([@bib15]), suggesting that TAM phenotypes may show differences in different tumour locations. Accordingly, in our analyses, intratumoural CD68^+^ TAMs did not associate with stage (*P*=0.629) or recurrence rate (*P*=0.619), whereas peritumoural CD68^+^ TAMs showed a trend towards lower cell densities in advancing stage (*P*=0.055) and in the presence of recurrences (*P*=0.080). These findings lend support to the importance of peritumoural TAMs in CRC defence irrespective of intratumoural TAMs. The potential alterations in TAM phenotypes depending on their distribution in the tumour will be the subject of future work, with reliable analyses requiring thorough validation of the methods used in their identification.

In addition to macrophages, the location of other tumour-associated inflammatory cell types may be important ([@bib9]). Our analysis identified T lymphocytes as the most frequent of the studied cell types, both in the tumour core and at the invasive front. Relative to FoxP3^+^ T~Reg~ cells, cytotoxic CD8^+^ T cells were slightly more common at the invasive front compared with the intratumoural stroma, indicating a higher cytotoxic activity at the invasive front. Moreover, the infiltrate at the invasive front had universally (excluding mast cells) higher inverse correlation with stage than the intratumoural infiltrate. This underlines the importance of dense peritumoural inflammatory cell infiltration -- comprising cells of both adaptive and innate immunity cells -- in restricting tumour growth, supporting the relevance of the K--M classification. Indeed, the invasive front of CRC is the site of important events in tumour progression including epithelial--mesenchymal transition ([@bib23]), and inflammatory reaction at the invasive front, specifically, has also earlier been proposed to be decisive for the clinical outcome of patients ([@bib42]).

Regardless of the short follow-up in our recurrence analysis, high CD3^+^ and FoxP3^+^ T-cell counts, in addition to high K--M score, significantly associated with lower recurrence rate. There is a need for standardisation of the evaluation of inflammatory cell infiltration in CRC to provide an effective prognostic and potentially predictive tool ([@bib27]). Immunoscore consisting of the densities of CD3^+^ and CD8^+^ T cells represents a creditable attempt to incorporate immune cell infiltration into cancer classification ([@bib10]), and our results here support the validity of CD3 and CD8 as markers of CRC immunity status. Immunoscore definitions and methods include accurate cell counts acquired with objective computer-based methods ([@bib10]), which provide excellent reproducibility ([@bib41]). However, the availability of computer-based immunohistochemistry analysis could hinder the introduction of Immunoscore, and at this point it is not known whether specific immunohistochemical markers would provide any additional information compared with the analysis of the inflammatory reaction from H&E slides ([@bib31]).

Besides the T-cell subsets included in Immunoscore ([@bib10]), K--M score has been shown to be reproducible and to harbour stage-independent prognostic value in several independent studies ([@bib17]; [@bib32]; [@bib29]). Therefore, K--M score has been cited as a rational point of comparison for the immunohistochemical inflammatory markers ([@bib31]). Our present study provided important data on the contributions of individual cell types to K--M score and the interrelationships between different cell types, adding to the understanding of CRC-associated inflammatory reactions. However, the number of events and the time of observation limited our chances to firmly conclude the clinical impact of the components of immune cell infiltrate in CRC, and further investigation is also needed for a conclusive comparison of the prognostic value of K--M score relative to individual immunohistochemical inflammatory markers.

We utilised MLH1 and MSH2 immunohistochemistry for MSI screening, which has been attributed 92.3% sensitivity and 100% specificity in a large series of 1144 cases ([@bib18]). Relative to MLH1 and MSH2, an isolated loss in other MMR enzymes, MSH6 and PMS2, is infrequent in CRC, occurring in \<10--15% of Lynch syndrome cases and hardly ever in sporadic cases ([@bib28]). In our data, intra- and peritumoural CD3^+^ and CD8^+^ T cells were the only cell types to show significant associations with loss of either MLH1 or MSH2. However, the densities of several other cell types were also higher in the absence of MLH1 or MSH2, but the number of MMR-deficient cases (*n*=11) was too small to enable definite conclusions.

In summary, the density of overall CRC inflammatory cell infiltrate declines as tumour stage advances, likely depicting weakening immune response against the tumour. Especially, low K--M score and low T-cell counts predict higher recurrence rate. There are high positive correlations between the constituents of CRC inflammatory infiltrate, supporting the value of general inflammatory scoring.
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###### 

Click here for additional data file.

![**Representative images of immunohistochemical determination of eight inflammatory cell types in colorectal cancer: CD3 for T cells, CD8 for cytotoxic T cells, FoxP3 for regulatory T cells, CD68 for monocyte--macrophage lineage cells, CD83 for mature dendritic cells, CD1a for immature dendritic cells, mast cell tryptase for mast cells, and neutrophil elastase for neutrophilic granulocytes.**](bjc2013508f1){#fig1}

![**Dendrogram for hierarchical clustering of eight inflammatory cells in CRC.** Nearest neighbour method with standardised squared Euclidean distance was used. Mast cells and CD1a^+^ immature DCs clustered furthest from other cell types (at the bottom). These cell types also had the weakest associations with stage ([Table 4](#tbl4){ref-type="table"}). Instead, T cells, forming a cluster at the top along with CD83^+^ mature DCs, had the highest associations with stage ([Table 4](#tbl4){ref-type="table"}), recurrences ([Table 5](#tbl5){ref-type="table"}), and MMR deficiency ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}), supporting their importance in CRC defence.](bjc2013508f2){#fig2}

###### Patient characteristics

  ------------------------------------------ -------------
  **Colorectal cancer patients (*n*=117)**   
  Age, mean (s.d.)                           67.7 (11.2)
  **Sex**                                    
  Male                                       58 (49.6%)
  Female                                     59 (50.4%)
  **Preoperative RT/CRT**                    
  Yes                                        0 (0%)
  No                                         117 (100%)
  **Tumour location**                        
  Proximal colon                             49 (41.9%)
  Distal colon                               28 (23.9%)
  Rectum                                     40 (34.2%)
  **WHO grade**                              
  G1 (well)                                  16 (13.8%)
  G2 (moderately)                            86 (74.1%)
  G3 (poorly)                                14 (12.1%)
  **TNM stage**                              
  Stage I                                    19 (16.5%)
  Stage II                                   46 (40%)
  Stage III                                  32 (27.8%)
  Stage IV                                   18 (15.7%)
  **MMR screening status**                   
  MMR proficient                             105 (90.5%)
  MMR deficient                              11 (9.5%)
  ------------------------------------------ -------------

Abbreviations: MMR=mismatch repair; RT/CRT=radiotherapy or chemoradiotherapy; TNM=tumour, node, metastasis; WHO=World Health Organization.

###### Interrelationships between different inflammatory cell types in colorectal cancer

            **CD3s**    **CD3e**    **CD8i**    **CD8s**    **CD8e**    **FoxP3i**   **FoxP3s**   **CD68i**   **CD68s**   **CD83i**   **CD83s**   **CD1a_i**   **CD1a_s**   **Mast_i**   **Mast_s**   **Neut_i**   **Neut_s**
  -------- ----------- ----------- ----------- ----------- ----------- ------------ ------------ ----------- ----------- ----------- ----------- ------------ ------------ ------------ ------------ ------------ ------------
  CD3i      **0.714**   **0.603**   **0.529**   **0.368**   **0.531**   **0.594**    **0.495**    **0.391**   **0.254**   **0.449**   **0.424**     0.162        0.175        0.054        0.113      **0.210**      0.057
  CD3s                  **0.681**   **0.277**   **0.412**   **0.499**   **0.394**    **0.523**    **0.252**   **0.270**   **0.270**   **0.460**     0.012        0.142        −0.063       0.053        0.113        0.015
  CD3e                              **0.389**   **0.527**   **0.835**   **0.457**    **0.457**    **0.309**   **0.274**   **0.380**   **0.453**     0.020        0.051        0.038        0.052        0.174        0.067
  CD8i                                          **0.495**   **0.501**   **0.461**    **0.374**    **0.363**   **0.255**   **0.386**   **0.284**   **0.183**      0.097        0.147        0.014      **0.248**      0.086
  CD8s                                                      **0.621**   **0.345**    **0.508**      0.173     **0.221**   **0.224**   **0.399**     0.104        0.146        0.070        0.043        0.145        −0.003
  CD8e                                                                  **0.421**    **0.425**    **0.393**   **0.323**   **0.369**   **0.406**     −0.024       −0.009       0.062        −0.066     **0.209**      0.043
  FoxP3i                                                                             **0.691**    **0.384**     0.117     **0.591**   **0.268**   **0.409**    **0.325**      0.044        0.090      **0.413**    **0.254**
  FoxP3s                                                                                          **0.293**   **0.204**   **0.371**   **0.431**   **0.209**    **0.381**      0.061      **0.188**    **0.280**      0.179
  CD68i                                                                                                       **0.650**   **0.298**     0.146     **0.222**    **0.206**      0.060        0.175      **0.366**    **0.312**
  CD68s                                                                                                                   **0.220**   **0.263**     0.080        0.132        0.037      **0.235**    **0.238**    **0.312**
  CD83i                                                                                                                               **0.474**   **0.402**    **0.384**    **0.220**    **0.219**    **0.230**      0.114
  CD83s                                                                                                                                           **0.193**    **0.336**    **0.172**    **0.231**      0.045        −0.083
  CD1a_i                                                                                                                                                       **0.669**    **0.263**    **0.243**    **0.226**      0.138
  CD1a_s                                                                                                                                                                    **0.207**    **0.287**      0.169        0.080
  Mast_i                                                                                                                                                                                 **0.504**      0.019        −0.037
  Mast_s                                                                                                                                                                                                −0.018       0.157
  Neut_i                                                                                                                                                                                                           **0.674**

Abbreviations: e= intraepithelial; i=invasive front (peritumoural); Mast=mast cell tryptase; Neut=neutrophil elastase; s=stromal (intratumoural).

Numbers indicate Pearson\'s correlation coefficients for logarithmically transformed variables. Statistically significant coefficients are in bold.

###### Relationship between individual inflammatory cell types and Klintrup--Mäkinen classification of peritumoural inflammation

                                        **Peritumoural inflammation (Klintrup--Mäkinen classification)**                            
  ------------------------------------- ------------------------------------------------------------------ ------------------------ ---------
  CD3, invasive front                   401.0 (193.3--568.4)                                               1095.6 (640.6--1344.4)   1.9E−13
  CD3, stroma                           297.8 (133.9--509.5)                                               697.0 (454.9--1037.5)    4.5E−7
  CD3, intraepithelial                  16.9 (5.3--33.1)                                                   85.0 (22.9--128.9)       9.6E−9
  CD8, invasive front                   110.8 (56.3--240.6)                                                299.0 (155.9--574.5)     5.9E−7
  CD8, stroma                           65.7 (22.0--145.6)                                                 163.5 (60.1--311.3)      1.8E−4
  CD8, intraepithelial                  8.4 (2.6--23.4)                                                    48.9 (13.2--92.9)        1.1E−7
  FoxP3, invasive front                 105.5 (51.4--188.9)                                                227.0 (139.1--395.6)     1.3E−7
  FoxP3, stroma                         107.9 (51.2--181.3)                                                253.9 (108.6--396.3)     6.9E−4
  CD68, invasive front                  389.2 (245.0--614.1)                                               755.0 (538.4--1132.9)    6.8E−9
  CD68, stroma                          240.9 (167.7--462.5)                                               504.7 (297.2--731.3)     8.5E−6
  CD1a, invasive front                  7.7 (2.3--22.1)                                                    11.9 (5.7--18.2)         0.331
  CD1a, stroma                          6.6 (2.4--13.2)                                                    10.6 (3.1--15.8)         0.145
  CD83, invasive front                  3.5 (1.4--7.0)                                                     10.8 (7.1--19.3)         9.9E−10
  CD83, stroma                          3.2 (1.3--6.5)                                                     5.8 (2.2--12.0)          2.7E−3
  Mast cell tryptase, invasive front    37.5 (24.0--64.8)                                                  45.5 (27.3--82.1)        0.199
  Mast cell tryptase, stroma            34.0 (20.4--58.0)                                                  45.7 (25.4--73.3)        0.065
  Neutrophil elastase, invasive front   18.8 (7.0--105.8)                                                  111.8 (18.0--386.4)      1.1E−3
  Neutrophil elastase, stroma           22.5 (8.8--80.9)                                                   56.3 (17.9--141.9)       0.016

The *P-*values are for Mann--Whitney *U-*test.

###### Local inflammatory cell infiltration in different TNM (tumour, node, metastasis) stages

                                        **TNM stage**                                                                                 
  ------------------------------------- ------------------------ ---------------------- ---------------------- ---------------------- --------
  CD3, invasive front                   1120.2 (668.3--1253.3)   566.9 (397.1--867.7)   573.5 (307.9--927.8)   205.2 (146.1--434.4)   1.5E−5
  CD3, stroma                           735.1 (412.7--1187.4)    517.7 (223.9--858.6)   379.6 (225.1--651.5)   223.6 (110.8--510.3)   6.6E−3
  CD3, intraepithelial                  72.1 (23.9--159.4)       26.1 (10.2--97.8)      22.7 (14.1--78.7)      10.6 (4.8--35.6)       2.8E−3
  CD8, invasive front                   265.5 (159.4--495.9)     184.1 (100.2--381.1)   149.5 (74.1--436.1)    95.0 (25.0--176.3)     4.7E−3
  CD8, stroma                           175.9 (42.2--260.3)      98.8 (55.1--210.4)     91.7 (26.8--237.8)     25.6 (13.5--84.7)      8.5E−3
  CD8, intraepithelial                  23.9 (10.6--112.6)       22.0 (6.6--63.3)       27.3 (4.2--59.5)       6.2 (1.7--19.0)        0.012
  FoxP3, invasive front                 276.7 (222.8--416.2)     158.8 (85.3--312.7)    147.7 (74.8--280.2)    54.2 (27.0--106.6)     1.6E−7
  FoxP3, stroma                         250.9 (156.5--389.2)     142.8 (91.0--381.9)    121.7 (63.7--284.3)    42.5 (20.2--73.6)      9.7E−6
  CD68, invasive front                  619.0 (269.9--975.4)     647.1 (390.1--899.9)   495.9 (292.8--778.0)   361.1 (246.8--544.5)   0.055
  CD68, stroma                          277.9 (186.4--607.2)     410.3 (224.2--597.0)   393.7 (187.6--637.5)   311.3 (189.3--476.3)   0.629
  CD1a, invasive front                  16.2 (11.14--25.32)      10.4 (1.8--21.0)       10.6 (5.6--21.8)       4.0 (2.0--11.9)        0.012
  CD1a, stroma                          10.6 (7.6--22.9)         10.1 (2.7--15.3)       7.3 (3.5--12.9)        5.8 (1.0--15.3)        0.208
  CD83, invasive front                  14.1 (7.0--21.7)         6.3 (3.24--11.5)       8.57 (2.26--12.7)      2.3 (0.88--6.51)       3.2E−4
  CD83, stroma                          7.0 (2.6--16.3)          4.1 (1.7--7.7)         5.4 (2.7--8.7)         1.9 (0.55--4.9)        8.6E−3
  Mast cell tryptase, invasive front    65.7 (29.9--105.5)       38\. (24.4--82.1)      39.9 (24.0--69.8)      39.0 (24.2--50.1)      0.299
  Mast cell tryptase, stroma            56.3 (35.2--91.4)        36.1 (17.4--72.7)      37.2 (25.4--60.5)      39.3 (20.5--46.6)      0.163
  Neutrophil elastase, invasive front   98.5 (11.7-397.9)        60.7 (14.1--273.5)     52.1 (10.8--291.5)     9.1 (4.8--40.8)        0.079
  Neutrophil elastase, stroma           56.3 (9.4--123.1)        39.9 (10.6--166.3)     32.5 (7.6--100.8)      25.3 (8.79--128.6)     0.545

Numbers indicate cells mm^−2^. The *P-*values are for Kruskal--Wallis test.

###### The 24-month recurrence analysis

  **Variable**                          **AUC**   **95% CI**     **Cutoff (cells** **mm**^−**2**^)    **Log-rank** ***P-*****value**
  ------------------------------------- --------- -------------- ----------------------------------- --------------------------------
  CD3, invasive front                   0.655     0.502--0.808   600                                            **0.037**
  CD3, stroma                           0.659     0.526--0.793   580                                              0.095
  CD3, intraepithelial                  0.612     0.480--0.744   24                                               0.181
  CD8, invasive front                   0.522     0.346--0.698   110                                              0.220
  CD8, stroma                           0.624     0.464--0.784   80                                               0.150
  CD8, intraepithelial                  0.553     0.399--0.708   15                                               0.373
  FoxP3, invasive front                 0.699     0.551--0.847   150                                            **0.049**
  FoxP3, stroma                         0.691     0.543--0.839   125                                          **2.7E**−**3**
  CD68, invasive front                  0.637     0.487--0.788   480                                              0.080
  CD68, stroma                          0.499     0.340--0.659   380                                              0.619
  CD1a, invasive front                  0.469     0.332--0.606   16                                               0.963
  CD1a, stroma                          0.475     0.313--0.636   10                                               0.472
  CD83, invasive front                  0.525     0.360--0.690   13                                               0.514
  CD83, stroma                          0.525     0.374--0.677   7                                                0.351
  Mast cell tryptase, invasive front    0.498     0.328--0.668   40                                               0.525
  Mast cell tryptase, stroma            0.490     0.346--0.633   40                                               0.837
  Neutrophil elastase, invasive front   0.527     0.375--0.679   150                                              0.413
  Neutrophil elastase, stroma           0.564     0.405--0.722   110                                              0.150
  Klintrup--Mäkinen score (4-tiered)    0.681     0.548--0.840   ---                                            **0.024**
  Klintrup--Mäkinen score (2-tiered)    0.626     0.470--0.781   ---                                              0.093

Abbreviations: AUC=area under the curve; CI=confidence interval.

The table presents receiver operating characteristics (ROC) analysis, AUCs, and log-rank *P-*values for different inflammatory variables in detecting recurrences. Statistically significant *P-*values are in bold.
